Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services within the Department of Health and Human Services relating to Medicare coverage for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions.
Other Bill Titles (2 more) 9/27/2007--Introduced.
Disapproves a specified rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to Medicare coverage for the use of erythropoiesis stimulating agents in cancer and related neoplastic condition... moreSee Full Bill Text
Committees
Amendments
This bill has no amendments.
Bill Status
| Introduced | ![]() | Voted on by House |
| September 27, 2007 |
In the News
October 19, 2007 FDA Agrees With CMS’ Coverage Decision on ESAs
recently introduced HJ Res. 54, which would reverse CMS’ national coverage decision. The Senate passed a resolution by unanimous consent asking the CMS to ...
October 18, 2007 Groups Ask Congress Not To Intervene in CMS Decision on Anemia Drugs
introduced a Congressional Review Act joint resolution (HJ Res 54) that would require CMS to reverse the decision. Amgen, J&J, the American Society of ...
October 02, 2007 CMS Required To Reverse Medicare Coverage Decision For Anemia ...
on Thursday introduced a bill (HJ Res 54) that would reverse a CMS decision to limit Medicare coverage for use of anemia medications -- Aranesp, ...
Blog Coverage
November 16, 2007 25 new messages in 14 topics - digest
joint resolution (HJ Res. 54) is sponsored by Rep. Anna Eshoo (D-CA), whose district includes Amgen's headquarters. It already has 26 co-sponsors. The resolution is adamantly supported by the American Society of Clinical Oncologists ...
October 19, 2007 Congress Asked Not To Intervene In CMS Decision On Anemia Drugs
introduced a Congressional Review Act joint resolution (HJ Res 54) that would require CMS to reverse the decision. Amgen, J&J, the American Society of Clinical Oncology, the American Society of Hematology, patient advocacy groups, ...
October 18, 2007 Congress Asked Not To Intervene In CMS Decision On Anemia Drugs
introduced a Congressional Review Act joint resolution (HJ Res 54) that would require CMS to reverse the decision. Amgen, J&J, the American Society of Clinical Oncology, the American Society of Hematology, patient advocacy groups, ...
Source: Buy Gold Tablet Blog Day








Rating Filter: 5
(Close help)
Comments
(Close help)
No Comments
Add A Comment